Lupin partners with Boehringer lngelheim

04 Sep 2019

Lupin and Boehringer lngelheim have entered into licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop Lupin's lead MEK inhibitor compound in combination with one of Boehringer lngelheim's innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad range of oncogenic KRAS mutations.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Related Lupin Ltd. Links:

Lupin Share Price

738.25 0.00 (0.00%) Nov 14, 18:01
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 410.05
Lupin 738.25
Dr. Reddys Lab 2734.00
Piramal Enterprises 1758.75
Cadila Healthcare 234.20
View more..
Sensex vs Lupin
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback

8055769463

8055769463